Next Article in Journal
Synthesis and Characterization of Poly(Lactic-Co-Glycolic Acid)–Paclitaxel (PLGA-PTX) Nanoparticles Evaluated in Ovarian Cancer Models
Previous Article in Journal
Bioactive Plant Compounds as Alternatives Against Antifungal Resistance in the Candida Strains
Previous Article in Special Issue
Emerging Approaches in Glioblastoma Treatment: Modulating the Extracellular Matrix Through Nanotechnology
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Review

Nanoparticles for Glioblastoma Treatment

by
Dorota Bartusik-Aebisher
1,
Kacper Rogóż
2 and
David Aebisher
3,*
1
Department of Biochemistry and General Chemistry, Collegium Medicum, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland
2
Student Scientific Club English Division, Collegium Medicum, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland
3
Department of Photomedicine and General Chemistry, Collegium Medicum, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland
*
Author to whom correspondence should be addressed.
Pharmaceutics 2025, 17(6), 688; https://doi.org/10.3390/pharmaceutics17060688
Submission received: 20 April 2025 / Revised: 20 May 2025 / Accepted: 21 May 2025 / Published: 23 May 2025
(This article belongs to the Special Issue Nano-Based Technology for Glioblastoma)

Abstract

GBM is the most common and aggressive primary brain tumor in adults, characterized by low survival rates, high recurrence, and resistance to conventional therapies. Traditional diagnostic and therapeutic methods remain limited due to the difficulty in permeating the blood–brain barrier (BBB), diffuse tumor cell infiltration, and tumor heterogeneity. In recent years, nano-based technologies have emerged as innovative approaches for the detection and treatment of GBM. A wide variety of nanocarriers, including dendrimers, liposomes, metallic nanoparticles, carbon nanotubes, carbon dots, extracellular vesicles, and many more demonstrate the ability to cross the BBB, precisely deliver therapeutic agents, and enhance the effects of radiotherapy and immunotherapy. Surface functionalization, peptide modification, and cell membrane coating improve the targeting capabilities of nanostructures toward GBM cells and enable the exploitation of their photothermal, magnetic, and optical properties. Furthermore, the development of miRNA nanosponge systems offers the simultaneous inhibition of multiple tumor growth mechanisms and the modulation of the immunosuppressive tumor microenvironment. This article presents current advancements in nanotechnology for GBM, with a particular focus on the characteristics and advantages of specific groups of nanoparticles, including their role in radiosensitization.
Keywords: glioblastoma; nanoparticles; radiosensitization; targeted therapy glioblastoma; nanoparticles; radiosensitization; targeted therapy

Share and Cite

MDPI and ACS Style

Bartusik-Aebisher, D.; Rogóż, K.; Aebisher, D. Nanoparticles for Glioblastoma Treatment. Pharmaceutics 2025, 17, 688. https://doi.org/10.3390/pharmaceutics17060688

AMA Style

Bartusik-Aebisher D, Rogóż K, Aebisher D. Nanoparticles for Glioblastoma Treatment. Pharmaceutics. 2025; 17(6):688. https://doi.org/10.3390/pharmaceutics17060688

Chicago/Turabian Style

Bartusik-Aebisher, Dorota, Kacper Rogóż, and David Aebisher. 2025. "Nanoparticles for Glioblastoma Treatment" Pharmaceutics 17, no. 6: 688. https://doi.org/10.3390/pharmaceutics17060688

APA Style

Bartusik-Aebisher, D., Rogóż, K., & Aebisher, D. (2025). Nanoparticles for Glioblastoma Treatment. Pharmaceutics, 17(6), 688. https://doi.org/10.3390/pharmaceutics17060688

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop